Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The safety and efficacy of HBI0101 for the treatment of R/R myeloma

In this video, Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses results from a study evaluating the safety and efficacy of HBI0101, a novel academic CAR-T, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Lebel summarizes the safety profile of this agent, as well as the response rates, rates of measurable residual disease (MRD) negativity, and progression-free survival (PFS) observed. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.